AR012989A1 - Novedosos inhibidores de sulfonamida de la farnesil-protein trasnferasa. - Google Patents

Novedosos inhibidores de sulfonamida de la farnesil-protein trasnferasa.

Info

Publication number
AR012989A1
AR012989A1 ARP980102859A ARP980102859A AR012989A1 AR 012989 A1 AR012989 A1 AR 012989A1 AR P980102859 A ARP980102859 A AR P980102859A AR P980102859 A ARP980102859 A AR P980102859A AR 012989 A1 AR012989 A1 AR 012989A1
Authority
AR
Argentina
Prior art keywords
novel sulfonamide
farnesil
protein transferase
sulfonamide inhibitors
inhibitors
Prior art date
Application number
ARP980102859A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR012989A1 publication Critical patent/AR012989A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen novedosos compuestos de sulfonamida y composiciones farmacéuticas que son inhibidores de la enzima proteína farnesil transferasa.También se describe un método para inhibir la funcion Ras y, por lo tanto, para inhibir eldesarr ollo anormal de las células. El método consiste en administrarel novedoso compuesto de sulfonamida a un sistema biologico. Especificamente, el método inhibe el desarrollo anormal de las células en mamíferos tales comoseres humanos.
ARP980102859A 1997-06-17 1998-06-16 Novedosos inhibidores de sulfonamida de la farnesil-protein trasnferasa. AR012989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87705097A 1997-06-17 1997-06-17

Publications (1)

Publication Number Publication Date
AR012989A1 true AR012989A1 (es) 2000-11-22

Family

ID=25369146

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102859A AR012989A1 (es) 1997-06-17 1998-06-16 Novedosos inhibidores de sulfonamida de la farnesil-protein trasnferasa.

Country Status (14)

Country Link
EP (1) EP0989980A1 (es)
JP (1) JP2002507192A (es)
KR (1) KR20010013826A (es)
CN (1) CN1267290A (es)
AR (1) AR012989A1 (es)
AU (1) AU8253698A (es)
CA (1) CA2293358C (es)
CO (1) CO4940475A1 (es)
HU (1) HUP0004627A2 (es)
IL (1) IL133393A0 (es)
NZ (1) NZ501619A (es)
PE (1) PE86199A1 (es)
WO (1) WO1998057949A1 (es)
ZA (1) ZA985218B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US7517884B2 (en) 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2429720C (en) * 2000-11-29 2009-12-29 Schering Corporation Tricyclic compounds useful for the inhibition of farnesyl protein transferase
WO2006055187A1 (en) 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
KR101464767B1 (ko) 2005-10-25 2014-11-24 칼립시스, 인코포레이티드 Ｐｐａｒ의 조절자의 염 및 대사질환을 치료하는 방법
US20080176861A1 (en) 2007-01-23 2008-07-24 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
BR112015019818A2 (pt) * 2013-02-19 2017-07-18 Icahn School Med Mount Sinai composto, uso de um composto, e, composição farmacêutica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76057A (en) * 1993-10-15 1997-06-30 Schering Corp Tricyclic sulfonamide compounds, pharmaceutical compositions containing them, which are useful for inhibition of g-protein function and for treatment of proliferative diseases and process for producing them
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CA2293358C (en) 2008-08-05
ZA985218B (en) 1998-12-15
PE86199A1 (es) 1999-09-24
CN1267290A (zh) 2000-09-20
AU8253698A (en) 1999-01-04
HUP0004627A2 (hu) 2001-10-28
NZ501619A (en) 2002-02-01
CO4940475A1 (es) 2000-07-24
IL133393A0 (en) 2001-04-30
JP2002507192A (ja) 2002-03-05
KR20010013826A (ko) 2001-02-26
WO1998057949A1 (en) 1998-12-23
CA2293358A1 (en) 1998-12-23
EP0989980A1 (en) 2000-04-05

Similar Documents

Publication Publication Date Title
Tanaka et al. Hydrophobic regions function in calmodulin-enzyme (s) interactions.
Chesney et al. Effect of platelet-activating factor (PAF) on human platelets
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
MX9206008A (es) Inhibidores de enzima proteolitica, derivados de sacarina 2-substituida.
TR199800825T2 (xx) Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri.
RU94015838A (ru) Производные бензофуранил- или бензотиофенилалкан-карбоновой кислоты, смесь их изомеров или отдельные изомеры и их соли
BR9809342A (pt) Composto, composição farmacêutica, e, uso do composto
FI942423A (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
Fenton et al. Biogenesis of the mitochondrial enzyme methylmalonyl-CoA mutase. Synthesis and processing of a precursor in a cell-free system and in cultured cells.
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
AR012989A1 (es) Novedosos inhibidores de sulfonamida de la farnesil-protein trasnferasa.
Hope et al. Secretory phospholipase A 2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A 2
EA200000240A1 (ru) Соединения, препятствующие эффекту раннего превращения лекарственных средств
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
EA199800544A1 (ru) Тиольные производные, обладающие ингибирующей активностью в отношении металлопептидаз
AR009809A1 (es) Derivados de 10,13,15-trioxatriciclo[9.2.1(9.6)]-pentadecanona, procedimientos para su preparacion y medicamentos que contienen estos compuestos
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.
Keraly et al. Inhibition by ticlopidine of PAF-acether-induced in vitro aggregation of rabbit and human platelets
BR0308601A (pt) inibidores de carboxipeptidase b de plasma
BR9816072A (pt) Composição clareadora da pele contendo um composto de ácido ascórbico
ATE299140T1 (de) Farnesyl-protein transferase inhibitoren
NO20003880L (no) Transfekterende midler som er sensitive overfor reduserende betingelser, farmasøytiske preparater inneholdende disse samt deres anvendelser

Legal Events

Date Code Title Description
FB Suspension of granting procedure